BioCryst Pharmaceuticals Inc. Insider Trading

BCRX

Last 12 months

Insiders sold $4.14M and bought nothing on the open market.

85% of the selling was scheduled in advance under 10b5-1 plans. Director Theresa Heggie sold 505K on Mar 20, 43% of their stake, outside a plan. The last open-market buy by an executive or director was in May 2024.

Net open-market

−$4.14M

0 buys · 8 sales

Under a 10b5-1 plan

85%

of the value sold

Insiders who bought / sold

0 / 4

executives and directors

Last open-market buy

May 2024

May 30, 2024

Get an email when BCRX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
May 18	Amy E McKee Director	SoldNo plan	11,180	$8.97	100K	26%	Form 4
May 13	Alane P Barnes Chief Legal Officer	Sold10b5-1 plan	62,500	$9.54	596K	13%	Form 4
Mar 20	Theresa Heggie Director	SoldNo plan	49,933	$10.11	505K	43%	Form 4
Mar 16	Alane P Barnes Chief Legal Officer	Sold10b5-1 plan	150,000	$9.15	$1.37M	27%	Form 4
Dec 22, 2025	Alane P Barnes Chief Legal Officer	Sold10b5-1 plan	21,773	$7.65	167K	5.2%	Form 4
Dec 15, 2025	Alane P Barnes Chief Legal Officer	Sold10b5-1 plan	21,210	$7.65	162K	6.3%	Form 4
Dec 1, 2025 – Dec 3, 2025	Alane P Barnes Chief Legal Officer	Sold10b5-1 plan 3 parts	161,680	$7.20 average	$1.16M	32%	Form 4
Nov 13, 2025	Machelle Sanders Director	Sold10b5-1 plan	9,600	$7.14	69K	24%	Form 4
Aug 13, 2025	Theresa Heggie Director	SoldNo plan	70,000	$8.51	596K	52%	Form 4
Dec 13, 2024	Nancy J Hutson Director	Sold10b5-1 plan	7,000	$7.54	53K	7.5%	Form 4

May 18No plan
Amy E McKee
Director · sold 11,180 at $8.97
100K
26% of stake
May 1310b5-1 plan
Alane P Barnes
Chief Legal Officer · sold 62,500 at $9.54
596K
13% of stake
Mar 20No plan
Theresa Heggie
Director · sold 49,933 at $10.11
505K
43% of stake
Mar 1610b5-1 plan
Alane P Barnes
Chief Legal Officer · sold 150,000 at $9.15
$1.37M
27% of stake
Dec 22, 202510b5-1 plan
Alane P Barnes
Chief Legal Officer · sold 21,773 at $7.65
167K
5.2% of stake
Dec 15, 202510b5-1 plan
Alane P Barnes
Chief Legal Officer · sold 21,210 at $7.65
162K
6.3% of stake
Dec 1, 2025 – Dec 3, 202510b5-1 plan
Alane P Barnes
Chief Legal Officer · sold 161,680 at avg $7.20
$1.16M
32% of stake
Nov 13, 202510b5-1 plan
Machelle Sanders
Director · sold 9,600 at $7.14
69K
24% of stake
Aug 13, 2025No plan
Theresa Heggie
Director · sold 70,000 at $8.51
596K
52% of stake
Dec 13, 202410b5-1 plan
Nancy J Hutson
Director · sold 7,000 at $7.54
53K
7.5% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch BCRX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with BCRX

CompareIntrinsic value

RGENRepligen Corporation

$178.20-0.04%35

TECHBio-Techne Corporation

$72.73+0.10%52

NVAXNovavax Inc.

$10.65+10.02%10

TARSTarsus Pharmaceuticals Inc.

$69.07-4.91%55

ADMAAdma Biologics Inc.

$10.48-5.67%82

KRYSKrystal Biotech Inc.

$310.84+1.90%44

TWSTTwist Bioscience Corporation

$142.58+1.63%40

IMCRImmunocore Holdings plc

$29.23-2.66%40

Held by ETFs

BCRX is in 51 US ETFs. The largest of them, with BCRX's weight in each:

Spot a number that looks wrong? Check it in BCRX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing BCRX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.